SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 14, 2005--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a collaboration with Imperial College London and the Medical Research Council (MRC) to discover the genetic variations associated with cancer, cardiovascular disease and diabetes. The agreement is part of Affymetrix’ translational medicine program, an initiative designed to accelerate clinical research and improve patient care by helping to bring more effective personalized tests and therapies to market faster.
